Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Shuai Xia(Shanghai Medical College of Fudan University), Shibo Jiang(Shanghai Medical College of Fudan University), Wei Xu(Beijing Geriatric Hospital), Hin Chu(University of Hong Kong), Jasper Fuk‐Woo Chan(Hong Kong Science and Technology Parks Corporation), Fanke Jiao(Fudan University), Qiaoshuai Lan(Fudan University), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Qian Wang, Lu Lu(Shanghai Medical College of Fudan University), Lijue Wang(Fudan University), Kenn Ka‐Heng Chik(University of Hong Kong), Chao Wang(Scripps Research Institute)
Cited by 40
Related Papers
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
|The Lancet|2020|9.6k
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
|Emerging Microbes & Infections|2020|3.3k
Consistent Detection of 2019 Novel Coronavirus in Saliva
|Clinical Infectious Diseases|2020|2k